Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB    UNC   BE0003739530

UCB (UNC)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on UCB
07:10a UCB : with a strong first half year 2017 – giving rise …
07/25 UCB : and Dermira Announce U.S. and EU Regulatory Submissions …
07/24 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP …
07/21 UCB : Bimekizumab Demonstrates Skin Clearance in Phase 2b Psoriasis Study with &..
07/17 UCB : and Amgen Provide Update on Regulatory Status of EVENITY …
07/06 UCB : Study Findings on Clinical Pharmacology Are Outlined in Reports from UCB S..
06/15 UCB : Outcome Capital Announces UCB Pharma Has Acquired Beryllium Discovery
06/14 UCB : New study illustrates large treatment gap in post-fracture care …
06/14 UCB : announces four-year imaging results demonstrating low disease progression ..
06/14 UCB : Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minima..
06/14 UCB : New UCB data demonstrates scientific innovation for immunology patients wi..
06/11 UCB : Research!America - Briefing
06/09 UCB : Research!America - Briefing
06/08 UCB : Transparency notification BlackRock, Inc.
06/02 UCB : Transparency notification
06/02 UCB : Transparency notifications BlackRock, Inc.
06/01 UCB : New Findings on Epilepsy from UCB S.A. Summarized (Patient emotions and pe..
06/01 UCB : Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study ..
05/29 UCB : Transparency notification
05/22 UCB : and Amgen announce top-line phase 3 data from …
05/17 UCB : Transparency notification
05/04 Attention Deficit Hyperactivity Disorder ADHD Drug Sales Market 2017 - Shire,..
04/28 UCB : ex-dividend day for annual dividend
04/27 UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose &hell..
04/24 UCB FIRST THREE MONTHS INTERIM REPOR :  UCB with …
04/20 UCB : Findings from UCB S.A. Provides New Data on Epilepsy (Health care cost ass..
04/19UCB SA : quaterly earnings release
04/10 UCB : U.S. Patent and Trademark Office confirms validity of patent …
04/10 UCB : Acquisition of own shares
04/07 UCB : Acquisition of own shares
04/04 UCB : and Q-State Biosciences Form Research Collaboration …
04/03 AMGEN : Ucb and amgen report new data at endo 2017 examining the option of a sec..
04/01 UCB : AND AMGEN REPORT NEW DATA AT ENDO 2017 EXAMINING …
03/24 UCB : General Meeting on 27 April 27 2017
03/24 UCB : Convening notice to attend the general meeting of shareholders
03/23 UCB : U.S. Patent and Trademark Office confirms validity of patent …
03/17 UCB : Brussels - Transparency notifications
03/16 UCB : Transparency notifications
03/10 UCB : Acquisition of own shares
03/09 UCB : Researchers from UCB S.A. Report New Studies and Findings in the Area of E..
03/09 UCB : Transparency notification
03/09 SCHEDULES OF CONTROLLED SUBSTANCES : Placement of Brivaracetam Into Schedule V
03/08 UCB : Transparency notification
03/07 UCB : Transparency notification
03/06 UCB : New CIMZIA (certolizumab pegol) data in moderate-to-severe plaque psoriasi..
03/06 UCB : First CIMZIA Study of Its Kind Showed Minimal to No …
03/04 UCB : New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque &hellip..
03/02 UCB : Transparency Notifications
02/24 UCB : Transparency notifications BlackRock, Inc.
02/24 UCB : Transparency notification Wellington Management Group LLP
02/23 UCB FULL YEAR REPORT 2016 : UCB demonstrates continued top and …
02/16 UCB : Transparency notification
02/09 UCB : Transparency notifications
02/08 UCB : Transparency notifications
01/25 UCB : Transparency notifications
01/19 UCB : files BRIVIACT® (brivaracetam) CV in the U.S. as …
01/19 UCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy &h..
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency Notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/06 Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
01/05 DERMIRA : Elects Emmanuel Caeymaex to Board of Directors
2016 DERMIRA,INC. (NASDAQ : DERM) Files An 8-K Departure of Directors or Certain Offi..
2016 UCB : Second CIMZIA (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy..
2016 UCB : Family Epilepsy Scholarship Program Announces 2016 Recipients
2016 UCB : Juno Biomedical Moving Forward with Regenerative Stroke Treatment
2016 UCB : The Lancet Publishes First Head-to-Head Study of Cimzia® (certolizumab peg..
2016 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU C..
2016 UCB : Patent Issued for Method for Producing Protein (USPTO 9476081)
2016 UCB : continues its growth path
2016 UCB : Transparency notification
1  2  3  4  5  6Next
Financials (€)
Sales 2017 4 306 M
EBIT 2017 931 M
Net income 2017 590 M
Debt 2017 554 M
Yield 2017 1,97%
P/E ratio 2017 18,50
P/E ratio 2018 15,60
EV / Sales 2017 2,89x
EV / Sales 2018 2,64x
Capitalization 11 908 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 17
Average target price 66,5 €
Spread / Average Target 8,7%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-1.19%13 979
JOHNSON & JOHNSON14.47%352 757
NOVARTIS7.69%222 032
ROCHE HOLDING LTD.4.08%220 038
PFIZER1.91%195 864
MERCK AND COMPANY4.98%169 033